Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in Rheumatoid Arthritis
NCT06857227Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial in rheumatoid arthritis (RA) comparing GNC-038 with Placebo (2 arms). Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 8 more. Started Mar 2025; status: recruiting.
02
Drugs
emfizatamab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06857227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857227.